GSK Raises Full-Year Sales Guidance for RSV Vaccine Arexvy Amid Strong Market Demand

Dec 11, 2023 08:20 CST Updated 08:20

GSK

Pharmaceutical R&D Manufacturer

Recent Tracking Companies

2seventybio，Abbvie，Alnylam，Amgen，ALX oncology，Argenx，Astrazeneca，Avidity，Bluebird，BMS，Biogen，Eisai，Eli Lilly，Genentech，Gilead，HCA，J&J，Legend，Medtronic，Merck, Moderna，Novartis，Pfizer，Pliant，Regeneron，Roche，Sanofi，Sarepta，Vertex

Selected Articles

1）$300 Billion Eli Lilly's Core Logic of 3x Growth in 5 Years

2）HCA: A 10,000-Word Article on the Ups and Downs of the U.S. Healthcare Industry Over the Past 60 Years!

3）5000-Word In-Depth Analysis: Founding a Biotech Company from Scratch Now vs. Then

4）The Symbiotic Path of Pharma and Biotech

5）9 Questions on the New Alzheimer's Drug: Peak Prediction? When Will It Be Launched? Who Is the BIC?

6）The Logic Behind America's Unreasonably High Drug Prices

On 11/30, GSK raised the full-year sales guidance for its RSV vaccine Arexvy.

Although the exact amount wasn't specified, it will definitely exceed the previously estimated £10 billion.

I estimate that the main reasons for the increase are twofold:

1) After entering winter this year, outbreaks of various respiratory infectious diseases have occurred globally, including RSV.

2) Will Pfizer's vaccine continue to be suppressed by GSK due to patent issues?

For more details, please refer to this:

Four Major Reasons for GSK's RSV Success (Content Not on the PPT)